Bioxcel Therapeutics Logo

Innovative Medicine Backed by the Power of AI

BioXcel Therapeutics, Inc. is a
commercial-stage biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence, or AI, approaches.

Innovative Medicine
Backed by the
Power of AI

BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence, or AI, techniques.

Innovative Medicine
Backed by the Power of AI

BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence, or AI, techniques.

Our Approach to Drug Development

AI-based Drug Development

Our neuroscience and immuno-oncology franchises utilize our AI
approach to drug identification and development

Neuroscience

BXCL501-Neuroscience-image

Immuno-Oncology

BXCL701-Immuno-Oncology-image

Latest News

Aug 09, 2022
BioXcel Therapeutics Reports Second Quarter 2022 Financial Results and Recent Operational HighlightsVIEW RELEASE
Aug 03, 2022
BioXcel Therapeutics to Participate at the Canaccord Genuity 42nd Annual Growth ConferenceVIEW RELEASE
Aug 01, 2022
BioXcel Therapeutics Announces NIH NIDA Grant to Columbia University to Support Further Studies of BXCL501 (Sublingual Dexmedetomidine) for Treating Opioid WithdrawalVIEW RELEASE

Stock Information

BioXcel Therapeutics, Inc.

Aug 12, 2022 04:00 PM

MARKET/SYMBOL

Nasdaq:

BTAI

PRICE

15.64

CHANGE

0.47 (3.1%)